The Association of Race, Ethnicity, and Insurance Status with the Visual Acuity of Retinoblastoma Survivors in the IRIS® Registry.

View Abstract

PURPOSE

To identify sociodemographic factors associated with the visual outcomes of retinoblastoma survivors.

METHODS

Retrospective cohort study using a US-based clinical data registry. All individuals < 18 years of age with a history of retinoblastoma in the Intelligent Research in Sight (IRIS®) Registry (1/1/2013-12/31/2020). The primary outcome was visual acuity below the threshold for legal blindness (20/200 or worse) in at least one eye. Multivariable logistic regression was used to evaluate the association between visual outcomes and age, sex, laterality, race, ethnicity, type of insurance, and geographic location.

RESULTS

This analysis included 1545 children with a history of retinoblastoma. The median length of follow-up was 4.1 years (IQR, 2.2-5.9 years) and the median age at most recent clinical visit was 12 years (IQR, 8-16 years). Retinoblastoma was unilateral in 54% of cases. Poor vision in at least one eye was identified in 78% of all children and poor vision in both eyes in 17% of those with bilateral disease. Poor visual outcomes were associated with unilateral diagnosis (OR, 1.55; 95% CI,1.13-2.12;  = .007), Black race (OR, 2.03; 95% CI, 1.19-3.47;  = .010), Hispanic ethnicity (OR, 1.65; 95% CI, 1.16-2.37;  = .006), and non-private insurance (OR, 1.47; 95% CI, 1.02-2.10;  = .037).

CONCLUSIONS

Poor visual outcomes appear to be more common among Black, Hispanic, and publicly insured children with a history of retinoblastoma, raising concerns regarding healthcare inequities. Primary care physicians should ensure that young children receive red reflex testing during routine visits and consider retinoblastoma in the differential diagnosis of abnormal eye exams.

Investigators
Abbreviation
Ophthalmic Epidemiol
Publication Date
2024-04-05
Page Numbers
1-7
Pubmed ID
38578693
Medium
Print-Electronic
Full Title
The Association of Race, Ethnicity, and Insurance Status with the Visual Acuity of Retinoblastoma Survivors in the IRIS® Registry.
Authors
Oke I, Gonzalez E, Elze T, Miller JW, Lorch AC, Hunter DG, Yeh JM, Diller LR, Wu AC,